Candriam Luxembourg S.c.a. buys $29,992,772 stake in Incyte Corporation (INCY)

Incyte Corporation (INCY) : Candriam Luxembourg S.c.a. scooped up 64,709 additional shares in Incyte Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 338,061 shares of Incyte Corporation which is valued at $29,992,772.Incyte Corporation makes up approximately 0.76% of Candriam Luxembourg S.c.a.’s portfolio.

Other Hedge Funds, Including , American Century Companies Inc boosted its stake in INCY in the latest quarter, The investment management firm added 181,061 additional shares and now holds a total of 1,157,815 shares of Incyte Corporation which is valued at $102,721,347. Incyte Corporation makes up approx 0.11% of American Century Companies Inc’s portfolio. Princeton Capital Management Inc added INCY to its portfolio by purchasing 10,309 company shares during the most recent quarter which is valued at $914,614. Incyte Corporation makes up approx 0.59% of Princeton Capital Management Inc’s portfolio.Nisa Investment Advisors boosted its stake in INCY in the latest quarter, The investment management firm added 18,400 additional shares and now holds a total of 20,100 shares of Incyte Corporation which is valued at $1,691,013. Incyte Corporation makes up approx 0.02% of Nisa Investment Advisors’s portfolio.Fisher Asset Management reduced its stake in INCY by selling 21 shares or 0.14% in the most recent quarter. The Hedge Fund company now holds 14,818 shares of INCY which is valued at $1,223,374.

Incyte Corporation opened for trading at $88.52 and hit $90.35 on the upside on Friday, eventually ending the session at $90.21, with a gain of 2.37% or 2.09 points. The heightened volatility saw the trading volume jump to 8,59,753 shares. Company has a market cap of $16,925 M.

On the company’s financial health, Incyte Corporation reported $0.12 EPS for the quarter, based on the information available during the earnings call on May 9, 2016. Analyst had a consensus estimate of $0.12. The company had revenue of $263.50 million for the quarter, compared to analysts expectations of $264.41 million. The company’s revenue was up 65.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.11 EPS.

Many Wall Street Analysts have commented on Incyte Corporation. RBC Capital Mkts Initiated Incyte Corporation on Jul 13, 2016 to “Outperform”, Price Target of the shares are set at $105.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company’s compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received development and commercialization rights f

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *